KOVE Medical Raises €1.7M for Fetal Surgery Preterm Birth Tech

Zurich-based medical technology innovator, KOVE Medical, has successfully closed a €1.7 million (CHF 1.6 million) funding round. This significant capital injection, backed by a syndicate of angel investors, will propel the development of an implantable device aimed at mitigating the critical risk of preterm birth following fetal surgery. The funds are earmarked to advance the company's technology towards crucial First-in-Human clinical trials.

The core innovation from KOVE Medical addresses a major limitation in prenatal interventions. Fetoscopy, a minimally invasive surgical technique used to treat serious fetal conditions like spina bifida and congenital diaphragmatic hernia, necessitates puncturing the uterine wall and amniotic sac. This breach, while essential for access, can compromise the fetal membrane, leading to premature rupture and subsequent preterm delivery – a complication that restricts the scope and advancement of fetal surgery.

KOVE Medical's proprietary device is designed to be deployed from within the amniotic cavity, effectively sealing the surgical entry point. Its unique design aims to stabilize the fetal membrane at the puncture site without requiring additional incisions, leveraging existing fetoscopic port access. The company highlights the device's rapid deployment, stating it can be positioned in under five minutes, a crucial factor in time-sensitive surgical scenarios.

This funding round underscores a robust trend of investment in European medtech companies throughout 2026. The sector has seen substantial capital flows, including significant rounds for firms like FineHeart (€83 million), Neurent Medical (€62.5 million), Xeltis (€20.5 million), SamanTree Medical (€20 million), and MedVasc (€2.2 million). In Switzerland alone, Xsensio's €6 million raise for its biochemical monitoring technology provides a comparable domestic benchmark for innovation in the medical device space.

The successful financing for KOVE Medical, co-founded by Yannick Devaud and Kurt Ruffieux and emerging from research at the University of Zurich and University Hospital Zurich, marks a pivotal moment. CEO Yannick Devaud expressed gratitude towards the team and the visionary angel investors, emphasizing the mission to address critical health issues at the earliest stages of life. This development is poised to enhance the safety and efficacy of prenatal surgical procedures, potentially expanding treatment options for a wider range of fetal conditions.